ARPA-H, the United States' "moonshot" agency dedicated to advancing scientific research and development, has launched a new project aimed at developing custom gene editing drugs. According to [1], this effort is part of ARPA-H's broader mission to accelerate progress in biotechnology and medicine. [2] does not provide specific details about the scope or potential applications of these gene editing drugs but notes that the initiative will focus on advancing existing technologies rather than creating entirely new ones. The announcement comes amid growing interest in gene editing as a tool for treating genetic diseases. [1] highlights that this investment is part of ARPA-H's efforts to support innovative research and development, which could lead to significant advancements in medical treatments.
ARPA-H Invests $160 Million in Gene Editing Drug Research
The US government's "moonshot" agency, ARPA-H, has announced a $160 million initiative to develop custom gene editing drugs.
Story stats
Single source
- Left (1)
- Center (1)
- Right (1)
Sources agree
- ARPA-H is investing in gene editing drug research.
- The initiative will focus on advancing existing technologies.
Sources differ
- [2] does not provide specific details about the scope or potential applications of these gene editing drugs.